Swiss drugmaker Novartis has made a five-year financial commitment of $250 million to fight neglected tropical diseases (NTDs) and malaria.

BioNTech has launched a new project aimed at developing what it hopes will be a well-tolerated and highly effective malaria vaccine for the African continent. The Mainz...